UroGen Pharma
Open
$29.55
Prev. Close
$29.55
High
$29.80
Low
$29.55
Market Snapshot
$1.45B
-10.9
-2.80
$90.4M
291
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Recently from Cashu
UroGen Pharma Reaches Settlement with Teva, Clarifying Market Path for Jelmyto and Generics
UroGen Pharma (Ticker: URGN) establishes a significant legal ground with its recent settlement and license agreement with Teva Pharmaceuticals concerning Jelmyto, its leading cancer treatment. This st…
UroGen Pharma Reports Revenue Growth Driven by Innovative Urological Therapies and Strategic Cost Management
UroGen Pharma Sees Growth in Innovative Urological Therapies UroGen Pharma announces a notable surge in performance, as reflected in its recently released Q4 earnings report. The company’s revenues fo…
UroGen Pharma Achieves Strong Q4 Growth with Innovative Urological Therapies Launch
UroGen Pharma Reports Strong Q4 Performance Driven by Innovative Therapies UroGen Pharma announces its fourth-quarter earnings, revealing revenues of $25 million, marking a 15% increase year-over-year…
UroGen Pharma's Upcoming Earnings Report Highlights Innovations in Urologic Therapies and Growth Potential
UroGen Pharma Poised to Showcase Innovations in Urologic Therapies UroGen Pharma, a prominent player in the biopharmaceutical industry, is set to release its quarterly earnings report on March 2, 2026…